There’s a ‘man in the moon’: Why our brains see human faces everywhere
It’s so commonplace we barely give it a second thought, but human brains seem hardwired to see human faces where there are none — in objects as varied… read more.
It’s so commonplace we barely give it a second thought, but human brains seem hardwired to see human faces where there are none — in objects as varied… read more.
“Migraine is one of the most common headache disorders, but only about half the people taking medication for it get real relief,” said study author Rohit Bhatia, M.D.,… read more.
Université de Genève One person in 2000 suffers from a microdeletion of chromosome 22 that can lead to the development of psychotic disorders, such as schizophrenia, in adolescence…. read more.
AstraZeneca and MSD’s Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with… read more.
Medtronic plc announced it has received FDA approval for Vanta, a high performance recharge-free implantable neurostimulator (INS) with a device life that can be optimized up to 11… read more.
Blocked blood vessels in the brains of stroke patients prevent oxygen-rich blood from getting to cells, causing severe damage. Plants and some microbes produce oxygen through photosynthesis. What… read more.
Carpal tunnel syndrome (CTS), which causes tingling and numbness in the hand, more commonly affects women than men and tends to peak around the age of menopause. A… read more.
Janssen, the Pharmaceutical Companies of Johnson & Johnson, announced that the European Commission (EC) has approved Ponvory (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis… read more.
Newly published papers further elucidate the mechanisms underlying pridopidine’s neuroprotective properties through activation of the Sigma-1 Receptor (S1R). Pridopidine enhances mitochondrial function and reduces mHTT-induced ER stress, which… read more.
Scientists have discovered that the way in which neurons are connected within regions of the brain, can be a better indicator of disease progression and treatment outcomes for… read more.
Horizon Therapeutics plc announced the publication of a new analysis of the pivotal Phase II/III N-MOmentum trial for Uplizna (inebilizumab-cdon), assessing the potential for reduced risk of worsening… read more.
An experimental treatment produced improvements in cognitive function and language in patients with fragile X syndrome, according to study results published on April 29 in Nature Medicine. Fragile X… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.